FDA Approves Genentech´s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
(World News Science)

Thursday, Aug 15, 2019 First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Genentech`s first FDA-approved tumor-agnostic medicine South San Francisco, CA -- August 15, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved RozlytrekTM (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has also granted accelerated approval to Rozlytrek for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic...